



Tufts Center for the Study of Drug Development

TUFTS UNIVERSITY

Impact REPORT

ANALYSIS AND INSIGHT INTO CRITICAL DRUG DEVELOPMENT ISSUES

Biotech products in Big Pharma clinical pipelines have grown dramatically

Large molecules represent dominant share of big Pharma sales

- The number of biotech products in clinical development grew 155% in 11 years, from 355 in 2001 to 907 in 2012.
- Financing of biotech research increased 10-fold, from \$10.5 billion in 2001 to \$103 billion in 2012.
- Worldwide growth in biotechnology product sales grew 353% between 2001 and 2012, from \$36 billion to \$163 billion.
- In 2012, the 21 largest pharmaceutical companies had 429 biotech products in clinical development, of which 58% were monoclonal antibody products.
- From 1998-02 to 2008-12, the number of biotech company acquisitions by Big Pharma increased five-fold—from 15 to 75—while the value of those deals jumped eight-fold.